Cargando…

Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]

BACKGROUND: Chronic psoriasis can negatively affect patients' lives. Assessing the impact of treatment on different aspects of a patient's health-related quality of life (HRQOL) is therefore important and relevant in trials of anti-psoriasis agents. The recombinant humanized IgG(1 )monoclo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ortonne, Jean-Paul, Shear, Neil, Shumack, Stephen, Henninger, Eric
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1343580/ https://www.ncbi.nlm.nih.gov/pubmed/16359548 http://dx.doi.org/10.1186/1471-5945-5-13

Ejemplares similares

Evaluation of efalizumab using safe psoriasis control
por: Papp, Kim A, et al.
Publicado: (2006)

Efalizumab in the treatment of psoriasis
por: Boehncke, Wolf-Henning
Publicado: (2007)

The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab
por: Pincelli, Carlo, et al.
Publicado: (2006)

Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
por: Lotti, Torello, et al.
Publicado: (2010)

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis
por: Leonardi, C, et al.
Publicado: (2008)

Efalizumab-induced severe thrombocytopenia can be resolved
por: Prignano, Francesca, et al.
Publicado: (2008)

Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series
por: Lowes, Michelle A, et al.
Publicado: (2005)

Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study
por: Takahashi, María Denise, et al.
Publicado: (2010)

Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series
por: Lowes, Michelle A, et al.
Publicado: (2007)

Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study Results
por: Stengel, Fernando M, et al.
Publicado: (2009)

Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence
por: Papp, Kim A, et al.
Publicado: (2006)

Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial
por: Katsambas, Andreas, et al.
Publicado: (2009)

BALB.NCT-Cpox(nct) is a unique mouse model of hereditary coproporphyria
por: Kang, Xiaojing, et al.
Publicado: (2023)

Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
por: Mahé, E., et al.
Publicado: (2022)

Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis
por: Cui, Chun-Hui, et al.
Publicado: (2015)

Is Clear Always Clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician’s Global Assessment (PGA) in Psoriasis Clearance
por: Wu, Albert G., et al.
Publicado: (2020)

Temperatures and blood counts in pediatric patients treated with chemotherapy for cancer, NCT01683370
por: Lavieri, Luana, et al.
Publicado: (2019)

Temperatures, diagnostics and treatment in pediatric cancer patients with fever in neutropenia, NCT01683370
por: Brack, Eva, et al.
Publicado: (2020)

Study protocol: a double blind placebo controlled trial examining the effect of domperidone on the composition of breast milk [NCT00308334]
por: Campbell-Yeo, Marsha L, et al.
Publicado: (2006)

Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
por: Kimball, Alexa B., et al.
Publicado: (2021)

Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
por: Tyring, Stephen K., et al.
Publicado: (2023)

Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor
por: de Groot, Marjan, et al.
Publicado: (2007)

Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
por: Singh, Sanminder, et al.
Publicado: (2018)

Predictive models for IOPs measured with NCT, GAT, and ORA among patients undergoing SMILE
por: Han, Tian, et al.
Publicado: (2022)

Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial [NCT00029289]
por: Bahrami, Hossein, et al.
Publicado: (2006)

Evaluation and Analysis of Environmental Noise Levels in NCT of Delhi, India
por: Chauhan, B. S., et al.
Publicado: (2023)

The internal thoracic artery skeletonization study: A paired, within-patient comparison [NCT00265499]
por: Boodhwani, Munir, et al.
Publicado: (2006)

Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog
por: Natelson, Ethan A., et al.
Publicado: (2013)

Local steroid injection for moderately severe idiopathic carpal tunnel syndrome: Protocol of a randomized double-blind placebo-controlled trial (NCT 00806871)
por: Flondell, Magnus, et al.
Publicado: (2010)

Development and psychometric validation of the REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and clinicians
por: Gilet, H, et al.
Publicado: (2015)

ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)
por: Hoeppner, Jens, et al.
Publicado: (2016)

Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Paller, A.S., et al.
Publicado: (2020)

Vital signs in pediatric oncology patients assessed by continuous recording with a wearable device, NCT04134429
por: Haemmerli, Marion, et al.
Publicado: (2022)

Safety and efficacy of sorafenib in patients with advanced thyroid carcinoma: a phase II study (NCT02084732)
por: Fierro-Maya, Luis Felipe, et al.
Publicado: (2021)

How geoarchaeology and landscape archaeology contribute to niche construction theory (NCT)
por: Kluiving, Sjoerd J.
Publicado: (2015)

A comparison of NCT, Goldman application tonometry values with and without fluorescein
por: Erdogan, Hakika, et al.
Publicado: (2018)

Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People’s Republic of China
por: Li, Cheng-Rang, et al.
Publicado: (2015)

Estimabl2: Is There a Need for Radioiodine Ablation in Low Risk Differentiated Thyroid Cancer (DTC) Patients?: Results From the French Randomized Phase III Prospective Trial on 776 Patients (NCT 01837745)
por: Leboulleux, Sophie, et al.
Publicado: (2021)

A randomised trial of non-invasive cardiac output monitoring to guide haemodynamic optimisation in high risk patients undergoing urgent surgical repair of proximal femoral fractures (ClearNOF trial NCT02382185)
por: Davies, S. J., et al.
Publicado: (2019)

Comparison of flow characteristics and vascular reactivity of radial artery and long saphenous vein grafts [NCT00139399]
por: Chong, William CF, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_3t5mobsm19us2kn721vcsifmjg